Tel Aviv, Feb 22, 2026, 09:47 (IST) — The market has closed.
- With the Tel Aviv Stock Exchange closed on Sunday, traders are looking to Monday for the local policy decision and tracking signals from global markets.
- Bank of Israel’s rate decision lands alongside shekel swings and a rush of big U.S. tech earnings all crowding the tape.
- Teva has drawn attention again following new U.S. regulatory developments connected to its long-acting schizophrenia therapy.
With Tel Aviv’s exchange now observing a Monday-to-Friday schedule, the market stays shut on Sunday. Eyes shift to the Bank of Israel, which is set to announce its rate decision Monday afternoon.
The key issue right now? Rates remain the main force in a market packed with banks and other names sensitive to borrowing costs. Any tweak to guidance can jolt local bond yields, shift the shekel, and usually sends equities moving too.
For traders beyond Israel, attention shifts to Nvidia’s earnings this week, a key moment as investors hunt for proof that AI investments are actually delivering. Any hint of risk aversion could show up fast.
The TA-35 index wrapped up Friday at 4,232.11, gaining 0.52% for the session and advancing around 1.1% for the week. The TA-125, broader in scope, settled at 4,202.67, rising 0.71% on Friday and notching about a 0.9% weekly lift, Investing.com data show.
The currency market isn’t making much noise, but the dollar held near 3.119 shekels on Sunday. Over the previous week, it bounced between roughly 3.087 and 3.130, according to Wise, which also pegged a recent high at about 3.144.
Teva announced the U.S. Food and Drug Administration has accepted its New Drug Application for TEV-’749, a once-a-month injectable olanzapine designed for adults dealing with schizophrenia. In a joint statement with Medincell, Teva pointed out there’s no long-acting olanzapine option currently available that skips the FDA’s Risk Evaluation and Mitigation Strategy—meaning patients often face certified treatment sites and required post-dose observation. “Treatment adherence remains a major challenge and unmet need,” said Eric Hughes at Teva. Teva Pharmaceuticals
Teva shares in Tel Aviv ended the session at 10,730 shekels, up roughly 0.85% from the prior 10,640 close, Investing.com data show.
But this week’s action isn’t confined to local rates or any lone stock. Banks’ rate-driven earnings, currency hits for exporters, and whatever’s happening with U.S. tech—Tel Aviv tends to feel those shifts fast, particularly with dual-listed shares.
The risk scenario isn’t hard to spot. Reuters flagged that U.S. military planning on Iran is already well developed, while President Donald Trump has floated the idea of limited strikes—a volatile combination with the potential to rattle sentiment and jolt energy prices.
